Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1071-1079

  Bartlett, Nancy L ^a   Niedzwiecki, D ^b   Johnson, J L ^b   Friedberg, J W ^c   Johnson, K B ^d   van Besien, K ^e   Zelenetz, A D ^f   Cheson, B D ^g   Canellos, G P ^c  

^a USA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Hodgkin's lymphoma; Liposomal doxorubicin; Recurrent; Salvage therapy; Vinorelbine

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; NAVELBINE; VINBLASTINE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; LARYNX DISORDER; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERICARDIAL EFFUSION; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; STRIDOR; SYNCOPE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HODGKIN DISEASE; HUMANS; MIDDLE AGED; NEUTROPENIA; PATIENT SELECTION; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINBLASTINE;

EID: 34447320514     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm090     Document Type: Article

References (30)

1. Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and oacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-3489.
2. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
3. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
4. Paltiel O, Rubinstein C, Or R et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003; 31: 565-569.
5. Kewalramani T, Nimer SD, Zelenetz AD et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673-679.
6. Constans M, Sureda A, Arranz R et al. Relapse after autologous stem cell transplantation for Hodgkin's lymphoma: Prognostic factors affecting long-term outcome. Eur J Haematol 2004; 73: 53.
7. Schmitz N, Haverkamp H, Josting A et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Proc ASCO 2005; 23: 562S.
8. Martin A, Fernandez-Jimenez MC, Caballero MD et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113: 161-171.
9. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
10. Jesting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230.
11. Aparicio J, Segura A, Garcerá S et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10: 593-595.
12. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 93: 3632-3636.
13. Linch DC, Goldstone AH, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
14. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5: 817-820.
15. Leveque D, Quoix E, Dumont P et al. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1993; 33: 176-178.
16. Horning SJ, Chao NJ, Negrin RS et al. high-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
17. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-2619.
18. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85: 926-929.
19. Green MR. Gemcitabine safety overview [review, 20 refs]. Semin Oncol 1996; 23: 32-35.
20. Orditura M, Quaglia F, Morgillo F et al. Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity. Oncol Rep 2004; 12: 549-556.
21. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy Cancer Invest 2001; 19: 424-436.
22. Stephenson J, Aylesworth C, Johnson T et al. A phase I study of gemcitabine plus vinorelbine on an every other week schedule. Proc ASCO 1998; 17: 253a Abstr 970.
23. Fracasso PM, Blum KA, Tan BR et al. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer 2002; 95: 2223-2229.
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
25. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Chau I, Harries M, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003; 120: 970-977.
27. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 14. 2003; 1762-1767.
28. Gridelli C, Frontini L, Perrone F et al. Gemcitabine plus vinorelbine in advanced non-small lung cancer: A phase II study of three different doses. Gem Vin investigators. Br J Cancer 2000; 83: 707-714.
29. Isokongas OP, Mattson K, Joensuu H et al. A phase II study of vinorelbine (VNR) and gemcitabine (GEM) in inoperable stage IIIB-IV NSCLC. Proc ASCO 1998; 17: 489a Abstr 1882.
30. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood [see comment]. N Engl. J Med 1991; 324: 808-815.